Autolus Therapeutics (AUTL) EBIT (2017 - 2025)

Autolus Therapeutics (AUTL) has 9 years of EBIT data on file, last reported at -$72.5 million in Q4 2025.

• For the quarter ending Q4 2025, EBIT rose 4.48% year-over-year to -$72.5 million; the trailing twelve-month figure through Dec 2025 stood at -$270.5 million (down 12.06% YoY), and the FY2025 full-year result was -$270.5 million, down 12.06% from the prior year.
• EBIT for Q4 2025 stood at -$72.5 million, down from -$71.6 million in the prior quarter.
• Across five years, EBIT topped out at -$11.6 million in Q4 2022 and bottomed at -$39.4 billion in Q3 2021.
• The 5-year median for EBIT is -$43.6 million (2023), against an average of -$2.0 billion.
• The widest annual swing landed in 2021, when EBIT plunged 87053.61%; it then jumped 99.91% in 2022.
• A 5-year view of EBIT shows it stood at -$23.0 million in 2021, then jumped by 49.43% to -$11.6 million in 2022, then sank by 357.26% to -$53.3 million in 2023, then plunged by 42.41% to -$75.9 million in 2024, then rose by 4.48% to -$72.5 million in 2025.
• The last three EBIT figures came in at -$72.5 million (Q4 2025), -$71.6 million (Q3 2025), and -$61.2 million (Q2 2025), per Business Quant data.

Peer Comparison